Spasmolytic A29
From Wikipedia, the free encyclopedia
Antispasmodic drug
This article needs more citations . Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources:"Spasmolytic A29"–news · newspapers · books · scholar · JSTOR (January 2025) (Learn how and when to remove this message)
Find sources:"Spasmolytic A29"–news · newspapers · books · scholar · JSTOR (January 2025) (Learn how and when to remove this message)
Pharmaceutical compound
| Clinical data | |
|---|---|
| Other names | N,N-Dimethyl-4,4-diphenylbut-3-en-2-amine |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H21N |
| Molar mass | 251.373g·mol−1 |
| 3D model (JSmol) | |
| |
A29[1] [2] is a spasmolytic drug. It not used by itself but is co-administered with ketobemidone in a formulation sold as Ketogan. It is an analog of both amitriptyline and diphenhydramine.
See also
[edit ]References
[edit ]- ↑ PETERSEN PV (1951). "Studies on a new spasmolytic compound 1,1-diphenyl-3-dimethylaminobutene-1 (A29), related to methadone, and on the combined use of this compound and a potent analgesic, ketobemidone (A21)". Acta Pharmacologica et Toxicologica. 7 (1): 51–64. doi:10.1111/j.1600-0773.1951.tb02849.x. PMID 14829296.
- ↑ Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H (September 1998). "Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists". Biochemical Pharmacology. 56 (5): 553–9. doi:10.1016/s0006-2952(98)00088-4. PMID 9783723.
